TCL Archive “Too much [of NCI’s] planning is reactive rather than proactive. As a consequence, vision suffers.” July 7, 1995
TCL Archive More Cost-Effective To Use Cetuximab In Patients With Wild-Type KRAS Gene August 28, 2009
TCL Archive FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly. May 6, 2005
TCL Archive Duke Researchers Retract Paper from Blood; Dozens of Retractions of Potti’s Work Expected September 9, 2011
